Telix registers Phase 3 study of [18F]FET PET in brain metastases
The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.
Primary source
ClinicalTrials.gov registry record, November 12, 2026
[18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases
Read the source: [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation